A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | MicrobiomeTrials← Back to trialsNCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06-18Est. Completion: 2032-12-15
Enrollment target: 310 participants Locations- NHO Revive Research Institute LLC ( Site 0118), Lincoln, Nebraska, United States
- New York Oncology Hematology P.C ( Site 9000), Albany, New York, United States
- Clinica Adventista Belgrano ( Site 0304), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0303), Mar del Plata, Buenos Aires, Argentina
- Hospital Britanico de Buenos Aires ( Site 0305), Buenos Aires, Buenos Aires F.D., Argentina
- Sanatorio Parque ( Site 0302), Rosario, Santa Fe Province, Argentina
- Zhongshan Hospital Affiliated to Xiamen University ( Site 2213), Xiamen, Fujian, China
- The First Affiliated Hospital of Xiamen University. ( Site 2239), Xiamen, Fujian, China
- Guangxi Medical University Affiliated Tumor Hospital ( Site 2202), Qingxiu District, Guangxi, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2206), Wuhan, Hubei, China
- Hubei Cancer Hospital ( Site 2203), Wuhan, Hubei, China
- Nanjing Drum Tower Hospital ( Site 2224), Nanjing, Jiangsu, China
- Shandong Cancer Hospital ( Site 2200), Jinan, Shandong, China
Other microbiome trials you might be interested in
Non Small Cell Lung CancerNon-small Cell Lung CancerSmall-cell Lung CancerSmall Cell Lung Carcinoma
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxe…
Chicago, United StatesCompleted Jul 22, 2026
Advanced or Metastatic NSCLC
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination …
La Jolla, United StatesEst. completion May 4, 2026
Zhongshan Hospital affiliated to Fudan University ( Site 2215), Shanghai, Shanghai Municipality, ChinaShanxi Provincial Cancer Hospital ( Site 2227), Taiyuan, Shanxi, ChinaSichuan Cancer hospital. ( Site 2218), Chengdu, Sichuan, ChinaGemeinschaftspraxis für Hämatologie und Onkologie Münster ( Site 1108), Münster, North Rhine-Westphalia, GermanyAthens Medical Center ( Site 1201), Athens, Attica, GreeceMetaxa Cancer Hospital of Piraeus ( Site 1203), Piraeus, Attica, GreeceUniversity General Hospital of Alexandroupoli ( Site 1206), Alexandroupoli, East Macedonia and Thrace, GreeceRadboudumc ( Site 1504), Nijmegen, Gelderland, NetherlandsLeids Universitair Medisch Centrum ( Site 1503), Leiden, South Holland, NetherlandsUniversity Medical Center Groningen ( Site 1505), Groningen, NetherlandsNational Cancer Center ( Site 2505), Goyang-si, Kyonggi-do, South KoreaAjou University Hospital ( Site 2504), Suwon, Kyonggi-do, South KoreaChungbuk National University Hospital ( Site 2502), Cheongju-si, North Chungcheong, South KoreaKeimyung University Dongsan Hospital ( Site 2503), Daegu, Taegu-Kwangyokshi, South KoreaSeverance Hospital, Yonsei University Health System ( Site 2501), Seoul, South KoreaAsan Medical Center ( Site 2500), Seoul, South KoreaInstitut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 1807), Girona, Gerona, SpainFundación Instituto Valenciano de Oncología ( Site 1809), Valencia, Valenciana, Comunitat, SpainHospital Clinico San Carlos ( Site 1810), Madrid, SpainHospital Universitario La Paz ( Site 1808), Madrid, SpainHospital Universitario Virgen Macarena ( Site 1805), Seville, SpainTaipei Medical University Shuang Ho Hospital ( Site 2612), New Taipei City, TaiwanNational Cheng Kung University Hospital ( Site 2601), Tainan, TaiwanMackay Memorial Hospital ( Site 2611), Taipei, TaiwanRegional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 2002), Chernivtsi, Chernivetska Oblast, UkraineMedical Center "Mriya Med-Service"-Clinical Research Department ( Site 2012), Kryvyi Rih, Dnipropetrovsk Oblast, UkraineCommunal Non-Commercial Enterprise "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Reg ( Site 2006), Ivano-Frankivsk, Ivano-Frankivsk Oblast, UkrainePrivate Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 2013), Kropyvnytskyi, Kirovohrad Oblast, UkraineUkrainian Center of Tomotherapy ( Site 2014), Kropyvnytskyi, Kirovohrad Oblast, UkraineShalimov Institute of Surgery and Transplantation ( Site 2003), Kyiv, Kyivska Oblast, UkraineLviv Oncology Regional Treatment and Diagnostic Center ( Site 2009), Lviv, Lviv Oblast, UkraineLviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 2000), Lviv, Lviv Oblast, UkraineMunicipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council ( Site 2011), Odesa, Odesa Oblast, UkraineME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2001), Rivne, Rivne Oblast, UkraineCommunal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 2004), Vinnytsia, Vinnytsia Oblast, UkraineVolyn Regional Clinical Hospital ( Site 2010), Lutsk, Volyn Oblast, UkraineMedical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 2005), Kyiv, UkraineExtensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaRecurrent or RefractorySolid Tumors
Background:
Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (E…
Bethesda, United StatesEst. completion Jan 30, 2030